Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-11-08
2010-06-01
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S183000, C514S210210, C549S468000
Reexamination Certificate
active
07728033
ABSTRACT:
The present invention relates to a method of treating diabetic nephropathy with a combination of an immunosuppressive agent and an ACE inhibitor.
REFERENCES:
patent: 2 233 748 (1999-09-01), None
patent: WO 01/97809 (2001-12-01), None
patent: WO 2004/098587 (2004-11-01), None
Hasslacher et al. “Natural Course of Diabetic Nephropathy”. 2001, Chapter 2 from the book Diabetic Nephropathy, Edited by Christoph Hasslacher. John Wiley & Sons, Ltd. pp. 19-37.
Richter et al. Proceedings of the National Academy of Science (PNAS). 1929, vol. 15, pp. 570-578.
Ojogho et al. Pediatrics Transplantation. Apr. 2003, vol. 7, Issue 2, pp. 137-141.
Lewis et al. New England Journal of Medicine, 1993, vol. 329, No. 20, p. 1456-1462.
Manjunath et al. Post Graduate Medicine, 2001, vol. 110, No. 6, pp. 1-13.
BIOCON-press release, May 1, 2003, pp. 1-2.
EUCLID Study, Lancet, 1997, vol. 349, pp. 1787-1792.
Webster Ninth New Collegiate Dictionary. 2000, Definition of Prevention p. 1.
Webster Ninth New Collegiate Dictionary. 2000, Definition of Halt, p. 1.
Rossing et al. Diabetes, 1997, vol. 46, Issue 3, pp. 481-487.
Hao, et al., “Mycophenolate Mofetil Can Prevent the Development of Diabetes in BB Rats”Ann. NY Acad. Sci. 696: 328-332, 1993.
Remuzzi, et al., “Combining an Antiproteinuric Approach with Mycophenolate Mofetil Fully Suppresses Progressive Nephropathy of Experimental Animals”,J. Am. Soc. Nephrol., 10: 1542-1549, 1999.
Utimura, et al., “Mycophenolate Mofetil Prevents the Development of Glomerular Injury in Experimental Diabetes”,Kidney International, 63: 209-216, 2003.
Dooley, M., et al., “Mycophenolate Mofetil Therapy in Lupus Nephritis: Clinical Observations”J. American Soc. Nephrology10:4 833-839, 1999.
Arvind Atignal Shankara Rao
Moorthy Sachidananda
Choate Hall & Stewart LLP
Clinigene International Private Limited
Jean-Louis Samira
Padmanabhan Sreeni
Robidoux Andrea L. C.
LandOfFree
Mycophenolate mofetil in diabetic nephropathy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mycophenolate mofetil in diabetic nephropathy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mycophenolate mofetil in diabetic nephropathy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4240883